Introduction
Viral infections principally affecting the liver, are among the sexually transmitted diseases with the highest incidence worldwide. The most important of these is infection with hepatitis B virus (HBV), which is estimated to be responsible for chronic infection in at least 300 million individuals and is the ninth major cause of premature mortality. Hepatitis A virus (HAV) is rarely acquired sexually. Hepatitis E (HEV) has recently been characterised and is transmitted by the faecal-oral route, like HAV.'
Outbreaks of HEV infection have been described particularly in Asia. There is a high mortality among pregnant women (10%) for which there is so far no explanation. There is no evidence yet of sexual transmission of HEV; however the possibility of oro-anal transmission among homosexual men, as has been documented for HAV infection cannot be discounted. It will not be considered further here. Hepatitis D virus (HDV) affects only those simultaneously or already, chronically, infected with HBV. Sexual transmission does occur, but in developed countries most infections are associated with injecting drug use.
Hepatitis C virus (HCV) is another agent which has been recently characterised and is the major cause of parenterally transmitted non-A, non-B hepatitis (NANBH).2 Although the physico-chemical properties of the virus had been predicted correctly, for some years it eluded further characterisation owing to the low titre of virus in serum. Using serum known to have transmitted NANBH, Choo et al eventually cloned a sequence from a nonstructural gene (NS4). 3 The product of this gene reacted with other NANBH sera, and was used to make the first diagnostic assay for antibodies to HCV.4 HCV is a small RNA virus (9.1 kilobases) most closely related to the flaviviruses (eg dengue fever virus) and pestiviruses.5 By analogy with these viruses, there are nucleocapsid and envelope proteins coded for at the 5' end, and four non-structural gene products. Initial studies employing the first generation anti-HCV assay were complicated by the lack of a confirmatory assay. False positive reactions were suspected with sera from patients with chronic liver disease6 and from tropical communities.7 Second generation assays include a structural (nucleocapsid) gene-product. About 80% of cases of posttransfusion hepatitis are now attributable to HCV,8 although other antibody-antigen systems may be identified which will reveal additional cases. Delayed seroconversion after acute infection is common. Compared with the first-generation, second-generation anti-HCV assays are more likely to detect infection within 6 weeks (60% versus 45%; MJ Alter Evidence for the role of heterosexual intercourse in the transmission of HBV infection was obtained from an early prevalence study at a genitourinary medicine (GUM) clinic in which a raised prevalence of HBV markers, compared with the general population, was found and HBV marker prevalence was associated with a higher number of sexual part- Recommendations for the control of HBV infection in general, and sexual transmission in particular86 must take account of the widely varying prevalences in different countries not only between industrialised and less developed countries but even for example within Europe. In Italy the prevalence of infection is sufficiently high to have lead to a decision to give routine infant and adolescent immunisation. These measures, particularly infant immunisation alone, will take many years to affect the rate of sexual transmission of HBV infection.
In countries highly endemic for HBV infection, for example those in South-East Asia,86 most infections occur by vertical transmission or by horizontal transmission among young children. These are the main sources of chronic infections and those responsible for the maintenance of infection in the population. Universal immunisation of infants is therefore the primary control strategy. However, the risk of sexual transmission is still high for the 40-60% of the population who have reached adulthood without having been exposed, because of the high prevalence of carriers in the population. This situation will persist until the first cohorts of immunised children reach adulthood. In these circumstances a targeted vaccine policy for sexual contacts, sex industry workers, injecting drug users and homosexual men, in addition to universal infant immunisation may still be appropriate.
In the United States, a policy of selective immunisation of neonates at high risk of HBV infection has now been replaced by a policy of universal infant immunisation. Consideration is now being given to introducing universal adolescent immunisation, which would then be phased out when the first cohort of immunised infants reached adolescence. 87 In the United Kingdom, a country with a low prevalence of infection, those recommended to receive hepatitis B vaccine include sexual and household contacts of known HBsAg-positive patients, injecting drug users and those who change sexual parmer frequently whether homosexual or heterosexual. 88 Although it has been shown to be costeffective to immunise Viral hepatitis remains an important sexually transmitted disease worldwide. Hepatitis B is preventable, although strategies for the use of hepatitis B vaccine need to be appropriate to the epidemiology of infection in particular populations. Prevention of post-transfusion hepatitis C will have largely been achieved, since screening of donations for anti-HCV has been implemented in many countries. The rapidly increasing knowledge ofhepatitis C will lead to more information concerning the risks and consequences of sexual transmission.
